Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Abstract

The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4), thereby augmenting antitumor immune responses. After decades in which a number of clinical trials were conducted, ipilimumab was the first therapy to improve overall survival in a randomized, controlled phase III trial of patients with advanced melanoma. These results led to the regulatory approval of ipilimumab at 3 mg/kg for the treatment of unresectable or metastatic melanoma. More than 17,000 patients worldwide have received ipilimumab, either as a commercial drug at 3 mg/kg or in clinical trials and expanded access programs at different doses. Consistent with its proposed mechanism of action, the most common toxicities associated with ipilimumab therapy are inflammatory in nature. These immune‐related adverse events were mostly reversible when effective treatment guidelines were followed. Importantly, long‐term follow‐up of patients who received ipilimumab in a phase III trial showed that 24% survived at least two years, and in phase II studies, a proportion of patients survived at least five years. Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 91

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60::277-300.

   Not in our library10.3322/caac.20073

3. 3.

   Korn EL, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 2008;26::527-534.

   Not in our library10.1200/jco.2007.12.7837

4. 4.

   Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future perspectives. Oncologist. 2011;16::5-24.

   Not in our library10.1634/theoncologist.2010-0190

5. 5.

   Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastases: a literature review. Cancer Control. 2009;16::248-255.

   Not in our library10.1177/107327480901600307

6. 6.

   Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 2010;20::1-10.

   Not in our library10.1097/cmr.0b013e328333bbc8

7. 7.

   Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer. 2004;40::1825-1836.

   Not in our library10.1016/j.ejca.2004.04.030

8. 8.

   Rosenberg SA. Raising the bar: the curative potential of human caner immunotherapy. Sci. Transl. Med. 2012;4::127ps8.

   Not in our library10.1126/scitranslmed.3003634

9. 9.

   Eggermont AM. Advances in systemic treatment of melanoma. Ann. Oncol. 2010;21(Suppl 7)):vii339-vii344.

   Not in our library10.1093/annonc/mdq364

10. 10.

    Hoos A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 2010;37::533-546.

    Not in our library10.1053/j.seminoncol.2010.09.015

11. 11.

    Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer. 2011;11::805-812.

    Not in our library10.1038/nrc3153

12. 12.

    Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013;5::215-229.

    Not in our library10.2217/imt.13.9

13. 13.

    Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363::711-723.

    Not in our library10.1056/nejmoa1003466

14. 14.

    Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011;364::2517-2526.

    Not in our library10.1056/nejmoa1104621

15. 15.

    Ribas A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013;31::616-622.

    Not in our library10.1200/jco.2012.44.6112

16. 16.

    Hoos A, et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010;102::1388-1397.

    Not in our library10.1093/jnci/djq310

17. 17.

    Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur. J. Cancer. 2011;47::2150-2157.

    Not in our library10.1016/j.ejca.2011.06.052

18. 18.

    Shaw HM, Nathan PD. Vemurafenib in melanoma. Expert Rev. Anticancer Ther. 2013;13::513-522.

    Not in our library10.1586/era.13.24

19. 19.

    McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006;26::154-158.

    Not in our library

20. 20.

    Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009;69::5269-5284.

    Not in our library10.1158/0008-5472.can-09-1750

21. 21.

    Waldmann TA. Immunotherapy: past, present and future. Nat. Med. 2003;9::269-277.

    Not in our library10.1038/nm0303-269

22. 22.

    Burnett FM. The concept of immunological surveillance. Prog. Exp. Tumor Res. 1970;13::1-27.

    Not in our library10.1159/000386035

23. 23.

    Lockyer CR, Gillatt DA. BCG immunotherapy for superficial bladder cancer. J. R. Soc. Med. 2001;94::119-123.

    Not in our library10.1177/014107680109400305

24. 24.

    Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 2012;23(Suppl 8)):viii6-viii9.

    Not in our library10.1093/annonc/mds256

25. 25.

    Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer. 2007;7::95-106.

    Not in our library10.1038/nrc2051

26. 26.

    Visser de KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer. 2006;6::24-37.

    Not in our library10.1038/nrc1782

27. 27.

    Abrams SI. Regulation of tumor progression by anti-neoplastic T cell responses. Cancer Biol. Ther. 2004;3::140-146.

    Not in our library10.4161/cbt.3.2.758

28. 28.

    Caligiuri MA. Human natural killer cells. Blood. 2008;112::461-469.

    Not in our library10.1182/blood-2007-09-077438

29. 29.

    Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006;90::297-339.

    Not in our library10.1016/s0065-2776(06)90008-x

30. 30.

    Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009;10::29-37.

    Not in our library10.1038/ni.1679

31. 31.

    DeVita VT, Rosenberg SA. Two hundred years of cancer research. N. Engl. J. Med. 2012;366::2207-2214.

    Not in our library10.1056/nejmra1204479

32. 32.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144::646-647.

    Not in our library10.1016/j.cell.2011.02.013

33. 33.

    Finn OJ. Cancer immunology. N. Engl. J. Med. 2008;358::2704-2715.

    Not in our library10.1056/nejmra072739

34. 34.

    Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 2007;17::275-287.

    Not in our library10.1016/j.semcancer.2007.06.009

35. 35.

    Hoos A, Britten CM, Huber C, O'Donnell-Tormey J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 2011;29::867-870.

    Not in our library10.1038/nbt.2000

36. 36.

    Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science. 1995;270::932-933.

    Not in our library10.1126/science.270.5238.932

37. 37.

    Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996;183::2533-2540.

    Not in our library10.1084/jem.183.6.2533

38. 38.

    Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 2006;18::206-213.

    Not in our library10.1016/j.coi.2006.01.011

39. 39.

    Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Oncol. Targets Ther. 2010;3::15-25.

    Not in our library10.2147/ott.s4833

40. 40.

    Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995;182::459-465.

    Not in our library10.1084/jem.182.2.459

41. 41.

    Tivol EA, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3::541-547.

    Not in our library10.1016/1074-7613(95)90125-6

42. 42.

    Waterhouse P, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270::985-988.

    Not in our library10.1126/science.270.5238.985

43. 43.

    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271::1734-1736.

    Not in our library10.1126/science.271.5256.1734

44. 44.

    Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998;58::5301-5304.

    Not in our library

45. 45.

    Elsas van A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999;190::355-366.

    Not in our library10.1084/jem.190.3.355

46. 46.

    Keler T, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 2003;171::6251-6259.

    Not in our library10.4049/jimmunol.171.11.6251

47. 47.

    Maker AV, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 2005;12::1005-1016.

    Not in our library10.1245/aso.2005.03.536

48. 48.

    Attia P, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005;23::6043-6053.

    Not in our library10.1200/jco.2005.06.205

49. 49.

    Hersh EM, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. N. Drugs. 2011;29::489-498.

    Not in our library10.1007/s10637-009-9376-8

50. 50.

    Slovin SF, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. 2013.

    Not in our library10.1093/annonc/mdt107

51. 51.

    Weber J, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 2009;15::5591-5598.

    Not in our library10.1158/1078-0432.ccr-09-1024

52. 52.

    Wolchok JD, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11::155-164.

    Not in our library10.1016/s1470-2045(09)70334-1

53. 53.

    O'Day SJ, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter, single-arm, phase II study. Ann. Oncol. 2010;21::1712-1717.

    Not in our library10.1093/annonc/mdq013

54. 54.
    A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma · 2011

    No notice
55. 55.

    Weber JS, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J. Immunother. 2012;35::89-97.

    Not in our library10.1097/cji.0b013e31823aa41c

56. 56.

    Dancygier H, Runne U, Leuschner U, et al. Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings. Hepatogastroenterology. 1983;30::93-95.

    Not in our library

57. 57.

    Frosch PJ, Czarnetzki BM, Macher E, et al. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J. Cancer Res. Clin. Oncol. 1979;95::281-286.

    Not in our library10.1007/bf00410649

58. 58.

    Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011;364::2507-2516.

    Not in our library10.1056/nejmoa1103782

59. 59.

    Shahabi V, et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol. Immunother. 2012;61::733-737.

    Not in our library10.1007/s00262-012-1227-3

60. 60.

    Margolin K, et al. Ipilimumab in patients with melanoma and brain metastases. Lancet Oncol. 2012;13::459-465.

    Not in our library10.1016/s1470-2045(12)70090-6

61. 61.

    Di Giacomo AM, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13::879-886.

    Not in our library10.1016/s1470-2045(12)70324-8

62. 62.

    Lebbé C, et al. Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials. Ann. Oncol. 2012;23(9).

    Not in our library10.1093/annonc/mdt161

63. 63.

    Prieto PA, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 2012;18::2039-2047.

    Not in our library10.1158/1078-0432.ccr-11-1823

64. 64.

    Maio M, et al. Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) plus dacarbazine (DTIC) in phase III study CA184–024. Ann. Oncol. 2012;23(9 Suppl).

    Not in our library

65. 65.

    Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012;30::2691-2697.

    Not in our library10.1200/jco.2012.41.6750

66. 66.

    YERVOY™ Full Prescribing Information.

    Not in our library

67. 67.

    Kaehler KC, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 2010;37::485-498.

    Not in our library10.1053/j.seminoncol.2010.09.003

68. 68.

    Pennock GK, Waterfield W, Wolchok JD. Patient responses to Ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am. J. Clin. Oncol. 2011;35::606-611.

    Not in our library10.1097/coc.0b013e318209cda9

69. 69.

    Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin. Cancer Res. 2009;15::7116-7118.

    Not in our library10.1158/1078-0432.ccr-09-2376

70. 70.

    Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009;15::7412-7420.

    Not in our library10.1158/1078-0432.ccr-09-1624

71. 71.

    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47::207-214.

    Not in our library10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6

72. 72.

    Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009;45::228-247.

    Not in our library10.1016/j.ejca.2008.10.026

73. 73.

    Lynch TJ, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012;30::2046-2054.

    Not in our library10.1200/jco.2011.38.4032

74. 74.

    Phase 3 trial in subjects with metastatic melanoma comparing 3 mg/kg ipilimumab versus 10 mg/kg ipilimumab (NCT01515189).

    Not in our library

75. 75.

    A phase I/II trial of vemurafenib and ipilimumab in subjects with V600 BRAF mutation-positive metastatic melanoma (NCT01400451).

    Not in our library

76. 76.

    Phase II safety study of vemurafenib followed by ipilimumab in subjects with V600 BRAF mutated advanced melanoma (NCT01673854).

    Not in our library

77. 77.

    Agarwala SS, O'Day SJ. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. Cancer Treat. Rev. 2010;37::133-142.

    Not in our library10.1016/j.ctrv.2010.06.001

78. 78.

    Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III or stage IV melanoma that has been removed by surgery (NCT01274338).

    Not in our library

79. 79.
    The Confluence of Radiotherapy &amp; Immunotherapy · 2012

    Not checked
80. 80.

    Harris TJ, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate. 2008;68::1319-1329.

    Not in our library10.1002/pros.20794

81. 81.

    Postow MA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012;366::925-931.

    Not in our library10.1056/nejmoa1112824

82. 82.

    A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma (NCT01480323).

    Not in our library10.1007/s00262-016-1944-0

83. 83.

    Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366::2443-2454.

    Not in our library10.1056/nejmoa1200690

84. 84.

    Dose-escalation study of combination BMS-936558 (MDX-1106) and ipilimumab in subjects with unresectable stage III or stage IV malignant melanoma (NCT01024231).

    Not in our library

85. 85.

    Murala S, Alli V, Kreisel K, et al. Current status of immunotherapy for the treatment of lung cancer. J. Thorac. Dis. 2010;2::237-244.

    Not in our library10.3978/j.issn.2072-1439.2010.11.6

86. 86.

    Reck M, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 2013;24::75-83.

    Not in our library10.1093/annonc/mds213

87. 87.

    Trial in extensive-disease small cell lung cancer (ED-SCLC) subjects comparing ipilimumab plus etoposide and platinum therapy to etoposide and platinum therapy alone(NCT01450761).

    Not in our library

88. 88.

    Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin (NCT01285609).

    Not in our library

89. 89.

    A phase II efficacy and safety study of ipilimumab monotherapy following completion of chemotherapy in recurrent platinum sensitive ovarian cancer subjects with residual measurable disease (NCT01611558).

    Not in our library

90. 90.

    An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy (NCT01585987).

    Not in our library

91. 91.

    Phase II trial of gemcitabine, cisplatin, plus ipilimumab as first-line treatment for patients with metastatic urothelial carcinoma: Hoosier Oncology Group GU10–148 (NCT01524991).

    Not in our library

Cited by papers we hold 6

• Current Advances in the Treatment of BRAF-Mutant Melanoma · 2020
  No notice
• Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab · 2018
  No notice
• CD4 and CD8 T lymphocyte interplay in controlling tumor growth · 2017
  No notice
• Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology · 2016
  Corrected
• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment · 2014
  No notice
• Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.